Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company's Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Since being founded in 2020, Tevogen Bio has taken a unique approach to both drug development and managing its business operations. The company launched is proprietary ExacTcell™ technology, designed to create accessible and disease ...